VistaGen Therapeutics Announces Pricing of Underwritten Public Offering
18 déc. 2020 06h25 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with...
VistaGen Therapeutics Announces Proposed Underwritten Public Offering
17 déc. 2020 16h01 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with...
VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
26 févr. 2019 09h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and...
VistaGen Therapeutics Announces Proposed Public Offering of Common Stock
25 févr. 2019 16h03 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and...
VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia
19 févr. 2019 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and...
VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
13 févr. 2019 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and...
VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results
12 févr. 2019 16h49 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for treating...
VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019
05 févr. 2019 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central...
AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies
31 janv. 2019 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central...
VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors
15 janv. 2019 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central...